MOUNTAIN VIEW, California, February 28, 2017 — Specific Technologies has been recognized as a National Institute of Allergy and Infectious Diseases (NIAID) Success Story, joining previous distinguished recipients including Illumina.
Specific Technologies, which has developed innovative paradigms for the detection, identification (ID) and antibiotic susceptibility testing (AST) of microorganisms growing in culture, announces today that the Company has been recognized as a “Success Story” by the National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovation Research (SBIR) program. Specific was one of just three companies awarded this honor last year and the only company named in the category of microbiology diagnostics. In part in recognition of this honor, Specific’s CEO has been invited by NIAID to address a distinguished audience of healthcare companies on the benefits of the National Institutes of Health (NIH) SBIR program at a NIAID-organized workshop to be held in New Orleans on September 7 – 8, 2017.
Specific joins prior NIAID Success Story recipients including Illumina. NIAID only honors a few companies for this recognition each year from amongst a set of nominees selected by a team within NIAID.
“We are honored to be recognized, and grateful for the substantial support provided to us by the NIAID SBIR program,” said Dr. Paul A. Rhodes, Chief Executive Officer of SpecificTechnologies. “In the last several months, Specific has made several announcements regarding
the funding we have received to advance development of its products for the global microbiology diagnostics market. The rise of antibiotic resistant infection is driving urgent need for faster determination of susceptibility, and our team is very proud of the fact that our innovative microbiology diagnostic solutions have been broadly recognized and supported by highly sophisticated and knowledgeable governmental and non-governmental organizations.”
“We are dedicated to revolutionizing the existing blood culture and susceptibility determination paradigms, and the support from organizations like NIAID enables us to expedite the commercialization of our unique solutions for the global marketplace,” said Rob Lozuk, President of Specific Technologies.
About the SpecID System
During growth in culture, bacteria produce small molecule volatile metabolites unique to their species and in some cases to their strain. Utilizing an inexpensive printed chemical sensor array to obtain a fingerprint that combines detection and identification into a simple, automated single step, the novel SpecID system identifies microorganism from a phenotypic metabolomic signature obtained during growth.
About Specific Technologies
Specific Technologies’ industry-leading team will develop clinically proven, regulated in vitro diagnostic systems based upon a unique, low cost and labor-saving metabolic signature technology that enables rapid detection, Gram status and identification (ID) of microorganisms directly in the blood culture bottle. The Company’s patented chemical fingerprint allows ID to be determined in a single, hands-free step, enabling faster time to result, laboratory costs savings and labor saving that speed time from sample-to-answer. Leveraging the same innovative technology, Specific is also developing an antibiotic susceptibility testing (AST) paradigm that would represent a new level of speed, ease of use and affordability in the all important phenotypic determination of antibiotic susceptibility. These two systems work in concert to offer a modernized next-generation work flow for the microbiology laboratory.
Specific Technologies is located in Mountain View, CA.
The Specific Technologies logo, Specific Technologies, and SpecID are registered trademarks or trademarks of Specific Technologies, Inc. in various jurisdictions.